PAR-25-153-Full-Announcement.html

This document is a Notice of Funding Opportunity (NOFO) for the federal grant opportunity titled "Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed)".

The NOFO is solicited by the National Cancer Institute (NCI) under the Department of Health and Human Services National Institutes of Health. It aims to support discovery research for the identification of validated hits relevant to health-related outcomes, including: 1) assay development for specific biological targets and disease mechanisms; 2) high throughput target-focused or phenotypic-based screening approaches to identify initial screening hits; 3) hit validation and characterization; and 4) hit-to-lead optimization. Eligible applicant types include nonprofits, for-profit organizations, state/local governments, higher education institutions, small businesses, and tribal organizations. The funding opportunity is assigned to the Cancer Treatment Research grant program (CFDA 93.395). The NOFO does not provide details on award dates, award values, or response deadlines.